|
[1]ARVANITI V, D'AMICO G, FEDE G, et al.Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J].Gastroenterology, 2010, 139 (4) :1246-1256.
|
|
[2]BUNCHORNTAVAKUL C, CHAMROONKUL N, CHAVALITDHAM-RONG D.Bacterial infections in cirrhosis:a critical review and practical guidance[J].World J Hepatol, 2016, 8 (6) :307.
|
|
[3]STEIB CJ, SCHEWE J, GERBES AL.Infection as a trigger for portal hypertension[J].Dig Dis, 2015, 33 (4) :570-576.
|
|
[4]LU L.Risk factors of liver cirrhosis ascites complicated with spontaneous bacterial peritonitis[J].China Med Herald, 2016, 13 (8) :140-142. (in Chinese) 陆琳.肝硬化腹水并发自发性细菌性腹膜炎的危险因素[J].中国医药导报, 2016, 13 (8) :140-142.
|
|
[5]DEVER JB, SHEIKH MY.Review article:spontaneous bacterial peritonitis-bacteriology, diagnosis, treatment, risk factors and prevention[J].Aliment Pharmacol Ther, 2015, 41 (11) :1116-1131.
|
|
[6]WU HQ, WANG H.Diagnosis and treatment of spontaneous bacterial peritonitis in patients with liver ascites[J].J Clin Hepatol, 2012, 28 (9) :651-653. (in Chinese) 吴海清, 王晖.肝硬化腹水伴自发性细菌性腹膜炎的诊断及治疗[J].临床肝胆病杂志, 2012, 28 (9) :651-653.
|
|
[7]SONG YY, JIANG YY.Research advances in diagnosis and treatment of spontaneous bacterial peritonitis[J].J Clin Hepatol, 2016, 32 (6) :1188-1191. (in Chinese) 宋媛媛, 江宇泳.自发性细菌性腹膜炎诊断与治疗的研究进展[J].临床肝胆病杂志, 2016, 32 (6) :1188-1191.
|
|
[8]AHGELI P, GUARDA S, FASOLATO S, et al.Switch therapy with ciprofloxacin vs.intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis:similar efficacy at lower cost[J].Aliment Pharmacol Ther, 2006, 23 (1) :75-84.
|
|
[9]LIAO XH.Management of spontaneous bacterial peritonitis in patients with liver cirrhosis[J].J Clin Hepatol, 2011, 27 (10) :1015-1018. (in Chinese) 缪晓辉.肝硬化合并自发性细菌性腹膜炎的处理[J].临床肝胆病杂志, 2011, 27 (10) :1015-1018.
|
|
[10]PIANO S, FASOLATO S, SALINAS F, et al.The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis:results of a randomized, controlled clinical trial[J].Hepatology, 2016, 63 (4) :1299-1309.
|
|
[11]JINDAL A, KUMAR M, BHADORIA AS, et al.A randomized open label study of‘imipenem vs.cefepime’in spontaneous bacterial peritonitis[J].Liver Int, 2016, 36 (5) :677-687.
|
|
[12]SAAB S, HERNANDEZ JC, CHI AC, et al.Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis:a meta-analysis[J].Am J Gastroenterol, 2009, 104 (4) :993-1001, 1002.
|
|
[13]LOOMBA R, WESLEY R, BAIN A, et al.Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis:meta-analysis[J].Clin Gastroenterol Hepatol, 2009, 7 (4) :487-493.
|
|
[14]FERNANDEZ J, NAVASA M, PLANAS R, et al.Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis[J].Gastroenterology, 2007, 133 (3) :818-824.
|
|
[15]TERG R, FASSIO E, GUEVARA M, et al.Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis:a randomized, placebo-controlled study[J].J Hepatol, 2008, 48 (5) :774-779.
|
|
[16]HANOUNEH MA, HANOUNEH IA, HASHASH JG, et al.The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis[J].J Clin Gastroenterol, 2012, 46 (8) :709-715.
|
|
[17]AAAEM M, ELSABAAWY M, ABDELRASHED M, et al.Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites:a prospective randomized open-label comparative multicenter study[J].Hepatol Int, 2016, 10 (2) :377-385.
|
|
[18]GINES P, RIMOLA A, PLANAS R, et al.Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis:results of a double-blind, placebo-controlled trial[J].Hepatology, 1990, 12 (4 Pt 1) :716-724.
|
|
[19]BAUER TM, FOLLO A, NAVASA M, et al.Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence[J].Dig Dis Sci, 2002, 47 (6) :1356-1361.
|
|
[20]ELFERT A, ABO AL, SOLIMAN S, et al.Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis[J].Eur J Gastroenterol Hepatol, 2016, 28 (12) :1450-1454.
|
|
[21]LEE YY.Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding[J].World J Gastroenterol, 2014, 20 (7) :1790.
|
|
[22]JALAN R, FERNANDEZ J, WIEST R, et al.Bacterial infections in cirrhosis:a position statement based on the EASL Special Conference 2013[J].J Hepatol, 2014, 60 (6) :1310-1324.
|
|
[23]HONG SN, KIM BJ, LEE SY, et al.Prospective randomized trial of intravenous ciprofloxacin for prevention of bacterial infection in cirrhotic patients with esophageal variceal bleeding[J].Taehan Kan Hakhoe Chi, 2002, 8 (3) :288-296.
|
|
[24]LIN YT, LO GH, LAI KH, et al.Prophylactic antibiotics in cirrhotics with upper gastrointestinal hemorrhage:a prospective, controlled trial[J].Chin Med J:Taibei, 2002, 65 (8) :365-371.
|
|
[25]HOU MC, LIN HC, LIU TT, et al.Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage:a randomized trial[J].Hepatology, 2004, 39 (3) :746-753.
|
|
[26]XU HW, WANG JH, TSAI MS, et al.The effects of cefazolin on cirrhotic patients with acute variceal hemorrhage after endoscopic interventions[J].Surg Endosc, 2011, 25 (9) :2911-2918.
|
|
[27]FERNNDEZ J, RUIZ del AL, GMEZ C, et al.Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage[J].Gastroenterology, 2006, 131 (4) :1049-1056, 1285.
|
|
[28]DIAZ FJ, ROMAN R, BUSTIOS C, et al.Ciprofloxacin vs cefazolin in the prevention of infection in cirrhotic patients with gastrointestinal bleeding[J].Rev Gastroenterol Peru, 2011, 31 (4) :319-323.
|
|
[29]WU CK, WANG JH, LEE CH, et al.The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at differen clinical stages of disease after endoscopic interventions for acute variceal hemorrhage[J].PLoS One, 2013, 8 (4) :e61666.
|
|
[30]BERNARD B, GRANGE JD, KHAC EN, et al.Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding:a meta-analysis[J].Hepatology, 1999, 29 (6) :1655-1661.
|
|
[31]PENG Y, QI XS, GUO XZ.Report of the Baveno VI Consensus Workshop:stratifying risk and individualizing care for portal hypertension[J].J Clin Hepatol, 2015, 31 (8) :1202-1207. (in Chinese) 彭颖, 祁兴顺, 郭晓钟.2015年BavenoⅥ共识:门静脉高压的风险分层及个体化管理[J].临床肝胆病杂志, 2015, 31 (8) :1202-1207.
|
|
[32]DENG H, QI XS, GUO XZ.UK guidelines on the management o variceal haemorrhage in cirrhosis patients (2015) :an excerpt o recommendations[J].J Clin Hepatol, 2015, 31 (6) :852-854. (in Chinese) 邓晗, 祁兴顺, 郭晓钟.《2015年英国肝硬化静脉曲张出血防治指南》摘译[J].临床肝胆病杂志, 2015, 31 (6) :852-854.
|
|
[33]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Endoscopy, Chinese Medical Asscciation.Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic protal hypertension[J].J Clin Hepatol, 2016, 32 (2) :203-219. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J].临床肝胆病杂志, 2016, 32 (2) :203-219.
|
|
[34]FERNANDEZ J, TANDON P, MENSA J, et al.Antibiotic prophylaxis in cirrhosis:good and bad[J].Hepatology, 2016, 63 (6) :2019-2031.
|
|
[35]FERNANDEZ J, ACEVEDO J, CASTRO M, et al.Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis:a prospective study[J].Hepatology, 2012, 55 (5) :1551-1561.
|
|
[36]de MATTOS AA, COSTABEBER AM, LIONCO LC, et al.Multi-resistant bacteria in spontaneous bacterial peritonitis:a new step in management?[J].World J Gastroenterol, 2014, 20 (39) :14079-14086.
|
DownLoad: